Gene · 3702
Papers2,789
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,789
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503). | Leuk Res | 2025 | 40479857 | PubTator, text mining | PubMed |
| Identification of potential inhibitors of interleukin-2-inducible T-cell kinase: insights from docking, molecular dynamics, MMPBSA and free energy landscape studies. | Amino Acids | 2025 | 40464789 | PubTator, text mining | PubMed |
| Harnessing cell size to separate genetically and functionally distinct dental pulp-derived mesenchymal stromal cell subpopulations. | J Biol Eng | 2025 | 40462207 | PubTator, text mining | PubMed |
| Shared genetic features inference among hypoxia-ischemia diseases in the presence of heterogenous omics data based on a novel risk assessment method. | Front Genet | 2025 | 40357364 | PubTator, text mining | PubMed |
| Targeting interleukin-2-inducible T cell kinase ameliorates immune-mediated aplastic anemia. | Cancer Immunol Immunother | 2025 | 40299061 | PubTator, text mining | PubMed |
| Transcriptomic sequencing of multiple salivary glands combined with bioinformatics analysis reveals key genes in primary Sjögren's syndrome. | Clin Rheumatol | 2025 | 40227387 | PubTator, text mining | PubMed |
| CD14+ monocytes: the immune communication hub in early vasculitis symptoms of Kawasaki disease. | Front Immunol | 2025 | 40207219 | PubTator, text mining | PubMed |
| Identifcation of the FGF family as therapeutic targets and prognostic biomarkers in the microenvironment of head and neck squamous cell carcinoma. | SLAS Technol | 2025 | 40086631 | PubTator, text mining | PubMed |
| Interleukin-2-inducible T-cell kinase inhibition to block NF-κB signaling exerts anti-tumor effects and enhances chemotherapy in NK/T-cell lymphoma. | Cancer Lett | 2025 | 40054659 | PubTator, text mining | PubMed |
| A Proteomics Outlook on the Molecular Effectors of CAR-T Cell Therapy in Cancer Management. | J Proteome Res | 2025 | 40047620 | PubTator, text mining | PubMed |
| Identification of a novel Azaspirooxindolinone-based PROTAC for selective BTK degradation and enhanced anticancer activity. | Bioorg Chem | 2025 | 40037026 | PubTator, text mining | PubMed |
| Characterization of the dual ITK/JAK3 small molecule covalent inhibitor ATI-2138. | J Pharmacol Exp Ther | 2025 | 40023606 | PubTator, text mining | PubMed |
| Design, synthesis, and biological evaluation of novel azaspirooxindolinone derivatives as potent inhibitors of ITK and BTK-dependent cancers. | Bioorg Med Chem | 2025 | 40015119 | PubTator, text mining | PubMed |
| Therapeutic Targeting of Interleukin-2-Inducible T-Cell Kinase (ITK) for Cancer and Immunological Disorders: Potential Next-Generation ITK Inhibitors. | OMICS | 2025 | 39969899 | PubTator, text mining | PubMed |
| Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma. | Front Immunol | 2025 | 39967670 | PubTator, text mining | PubMed |
| Exploration and Identification of Potential Biomarkers and Immune Cell Infiltration Analysis in Synovial Tissue of Rheumatoid Arthritis. | Int J Rheum Dis | 2025 | 39953769 | PubTator, text mining | PubMed |
| Purification and characterization of full-length monomeric TEC family kinase, ITK. | Protein Expr Purif | 2025 | 39894064 | PubTator, text mining | PubMed |
| A microglial kinase ITK mediating neuroinflammation and behavioral deficits in traumatic brain injury. | Mol Cell Neurosci | 2025 | 39864680 | PubTator, text mining | PubMed |
| Di-Genic Inheritance in Genodermatoses: Insights from Two Consanguineous Cases in a Reference Lebanese Center within the Middle East and North Africa (MENA) Region. | Dermatol Pract Concept | 2025 | 39853250 | PubTator, text mining | PubMed |
| A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells. | Nat Immunol | 2025 | 39779871 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3702/papers?page=5